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 1 
Introduction 1 
Thyroid eye disease (TED) is an autoimmune inflammatory disease affecting 2 
the orbit and periocular tissues. Previous studies have reported age-adjusted 3 
annual incidence rates of 42/million for TED of all severity (10/million for 4 
moderate to severe disease),1 and a prevalence of 0.25% within the 5 
developed world.2,3 Although the natural history of TED remains unclear, it 6 
typically has a period of activity over 6 to 12 months followed by slow 7 
improvement over 2 to 3 years.4 The disease may be disfiguring and has 8 
been shown to have a significant impact on physical and psychosocial 9 
wellbeing.2,5-7 As cheap and safe interventions may prevent progression from 10 
mild to severe TED8, there is an unmet need for early diagnosis, referral and 11 
treatment of these patients and these are key factors influencing patient 12 
outcome. For example, immunosuppressive therapies are most effective in 13 
the early active stages of TED and missing this window of opportunity is 14 
associated with worse outcomes.8,9  15 
In 2009, a consensus group of world opinion leaders on TED proposed the 16 
“Amsterdam Declaration”, that pledged to improve the care of patients with 17 
this condition.10 The Amsterdam Declaration set out a number of 5-year 18 
targets aimed at referral timelines and treatment strategies. They included: to 19 
halve the time from presentation to diagnosis of TED, and from diagnosis of 20 
TED to referral to a centre of excellence; appropriate management of thyroid 21 
dysfunction including use of radioiodine; and, the implementation of vigorous 22 
anti-smoking measures in patients with or at risk of developing TED.10 23 
 2 
The Thyroid Eye Disease Amsterdam Declaration Implementation Group UK 24 
(TEAMeD) was formed in 2010 in order to promote the objectives of the 25 
Amsterdam Declaration in the United Kingdom (UK). It comprises twelve 26 
representatives from key professional and patient-led stakeholders (including 27 
The Royal College of Ophthalmologists, the British Thyroid Association, the 28 
British Thyroid Foundation and the Thyroid Eye Disease Charitable Trust).10,11 29 
UK centres for the management of TED in the United Kingdom were invited to 30 
participate in an audit to provide baseline data in order to better define the 31 
Amsterdam 5-year targets and to highlight any major deficiencies in the 32 
current level of care provided for patients with TED in the United Kingdom. 33 
 34 
Materials and methods 35 
The National thyroid eye disease audit (UK) was a prospective non-36 
randomised cross-sectional multicentre observational study. The seven 37 
hospital departments who responded to the survey were: Moorfields Eye 38 
Hospital, London; University Hospital Cardiff; Royal Devon and Exeter 39 
Hospital; Queen’s Medical Centre, Nottingham; Queen Victoria Hospital, East 40 
Grinstead; Royal Hallamshire Hospital, Sheffield and Southampton General 41 
Hospital. 42 
 43 
During a three-month period from 01 June to 31 August 2014, consecutive 44 
adult patients with TED who presented to the specialist eye clinics at 45 
participating tertiary eye centres for the first time were asked (along with their 46 
examining ophthalmologist), to complete a standardised questionnaire. 47 
 3 
The questionnaire focused on the key 5-year targets of the Amsterdam 48 
Declaration and had six main domains: demographic information (age, 49 
gender); time from diagnosis to referral to a specialist centre; time from first 50 
symptoms to diagnosis; time from referral to review in tertiary centre; 51 
management of thyroid dysfunction; smoking; and thyroid eye disease 52 
classification (Appendix 1). Patients were identified as having “active” or 53 
“inactive” TED, based on the examiners’ overall clinical impression and the 54 
clinical activity score (CAS) (with a CAS of ≥3 being considered “active”).12 55 
The examining clinician interpreted the CAS in the context of the examination 56 
findings – for example, whether lid swelling was attributed to fat prolapse 57 
rather than eyelid oedema and after consideration of any clear history of a 58 
recent change in symptoms. This definition of active disease was the same as 59 
that employed by Perros et al.15 60 
 61 
All patients underwent a comprehensive ophthalmological examination 62 
including best-corrected visual acuity obtained with a Snellen chart, slit lamp 63 
biomicroscopy, exophthalmometry, Ishihara colour testing and assessment of 64 
ocular motility. Eye signs were assessed according to established European 65 
Group on Graves’ Orbitopathy (EUGOGO) protocols.13,14    66 
 67 
STATISTICAL ANALYSIS 68 
Completed forms were collated and analysed using summary statistics only. 69 
The study protocol was approved by Moorfields Eye Hospital, the lead centre 70 
for the study. The study was performed in compliance with good clinical 71 
practice guidelines and in accordance with the principles of the Declaration of 72 
 4 
Helsinki. Verbal consent was obtained from each patient after explanation of 73 
the purpose and process of the study. 74 
 75 
Results 76 
PATIENTS AND DEMOGRAPHICS 77 
Ninety-one patients (77 females; 85%) entered the study at a mean age 47.8 78 
years (SD14.1; median 48; range 19-80 years); the female:male ratio was 6:1. 79 
Fifteen questionnaires were returned without sufficient information to 80 
determine their specialist centre of origin and they were included in a group 81 
labelled ‘Other’ (Table 1).  82 
 83 
DURATION OF SYMPTOMS 84 
The median time was 2 months (range 0-204) between the first visit to any 85 
doctor with symptoms, until establishing a diagnosis of TED; the patient who 86 
waited 204 months for a diagnosis had inactive TED. The median time from 87 
diagnosis to initiating referral to a specialist eye clinic was 1.13 (range 0-72) 88 
months; it then took another median delay of 1 month (range 0-29) from the 89 
referral letter to actual review in a specialist eye clinic. Overall, the median 90 
time from first symptoms of thyroid eye disease to review in a specialist eye 91 
clinic was 7 months (range 0-600) (Figure 1). 92 
 93 
MANAGEMENT OF THYROID DYSFUNCTION 94 
The patient-reported management of thyroid dysfunction, including relapse of 95 
hyperthyroidism, was based on patients’ testimony: that is, information the 96 
patients might have received from their doctor(s) prior to the specialist clinic 97 
appointment and/or their perception of recurrent symptoms of abnormal 98 
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thyroid function. (Appendix 1). At the first specialist clinic appointment, 11% 99 
(10/91) patients reported still being hyperthyroid, 27% (25/91) reported a 100 
recurrence or ‘relapse’ of hyperthyroidism, and 22% (20/91) reported being 101 
hypothyroid in the last 2 years. Patients took a median of 6 months to control 102 
their thyroid function (range 0-60 months), 54% patients did not know their 103 
current thyroid status, and at least one quarter of patients reported episodes 104 
of dysthyroidism since their diagnosis (27% hyperthyroid). 105 
 106 
RADIOIODINE 107 
Thirteen percent (12/91) patients received radio-iodine, 3 of whom had thyroid 108 
eye disease at the time; 2 of these 3 patients had active TED and received 109 
prophylactic systemic steroids.   110 
 111 
Seven patients (all female) received radio-iodine whilst not having TED, but 112 
developed TED at a later date; their mean age at time of radio-iodine was 49 113 
years, and all had a history of poor thyroid control (2 were still hyperthyroid, 3 114 
didn’t know their thyroid status, one had never been euthyroid and another 115 
took 10 months to become euthyroid). Four of the 7 had relapse of 116 
hyperthyroidism and 4/7 had been hypothyroid in last 2 years. Five out of 7 117 
(71%) were smokers, of whom 4/5 (80%) had moderate to severe TED, 118 
whereas the 2 non-smokers had mild TED.  The mean Clinical Activity Score 119 
(CAS) for these 7 patients was 2.5 (SD1.98, median 2, range 0-6), with 5/7 120 
having “active” disease. 121 
 122 
SMOKING AND PATIENT AWARENESS OF THE IMPACT OF SMOKING ON TED 123 
 6 
Twenty-seven patients (30%) were current smokers and 28/91 (31%) were 124 
ex-smokers, but only 63% of the current smokers had been offered smoking 125 
cessation advice -- which was usually provided by the GP or the specialist eye 126 
clinic. Counselling and written information were the most common forms of 127 
help provided to encourage smoking cessation (Figure 2), with no clear 128 
difference in the modes of help provided across the different eye centres. 129 
Only one-third of patients (31%) were aware that smoking has an adverse 130 
effect on TED, although a quarter (26%) knew that treatments for TED (e.g. 131 
steroids/radiotherapy/surgery) are more effective in non-smokers or ex-132 
smokers than current smokers.  A fifth of patients (22%) knew a successful 133 
cure of thyrotoxicosis with anti-thyroid drugs was more likely in non-smokers, 134 
than in smokers (Table 2). 135 
 136 
THYROID EYE DISEASE CLASSIFICATION  137 
The mean CAS at presentation was 2/7 (SD 2.04; median 2; range 0-7) and 138 
65% had “active” disease: 46% patients had sufficient swelling to warrant 139 
treatment. 54% had no diplopia, 23% had intermittent diplopia, 8% had 140 
inconstant diplopia and 29% had constant diplopia. Seven percent were 141 
deemed to have a ‘cornea at risk and 4% had optic neuropathy. In terms of 142 
disease severity, 43% patients had mild, 53% had moderate-to-severe, and 143 
4% had sight-threatening disease (1 patient each at Moorfields, Nottingham 144 
and Sheffield) (Figure 3). 145 
 146 
Discussion 147 
 7 
Our patient population had a similar average age (48 years; SD 14 years) as 148 
that of a comparable study.15 Our gender ratio (female:male - 6:1), whilst the 149 
same as that in a recent study,16 was higher than the 3:1 reported by Perros 150 
et al in 2012.15  151 
 152 
The importance of early diagnosis and management to prevent progression of 153 
TED has been well documented. For patients with mild TED, a 6-month 154 
course of oral selenium (100 ฀g twice daily) was shown to significantly 155 
improve quality of life, reduce ocular involvement, and slow progression of the 156 
disease.17 Immunosuppressants such as systemic corticosteroids or orbital 157 
radiation) are only effective during the “active” phase of TED and so it is 158 
imperative that patients are identified and treated early, and the opportunity 159 
for effective intervention is not missed.18 160 
 161 
In 2008, Sasim et al19 found that 75% of patients with TED seen at a 162 
specialist eye centre had had the disease for over a year. Estcourt et al9 163 
reported that 33% of respondents waited more than 6 months from first 164 
consultation with any doctor to review at a specialist clinic; they also showed 165 
that patients treated at a specialist TED clinic were more likely to be satisfied 166 
with their ophthalmic treatment than those who did not attend a specialist 167 
clinic, and also that most UK patients with TED never reach specialist TED 168 
clinics or were referred too late. Their study also showed delays in diagnosis 169 
and referral of TED, limited access to specialist TED clinics and low patient 170 
satisfaction with treatment.9 171 
 8 
Our study has shown a median of 2 months (range 0-204) between patients 172 
seeing their first physician for ophthalmic symptoms and the diagnosis of 173 
TED, this being a favourable result compared to the PREGO study15 in which 174 
the median wait was 9 months (range 0-552) in 2012 and 16 months in 2000. 175 
Likewise, Estcourt et al9 showed 26% of survey responders waited more than 176 
12 months from first symptoms to diagnosis in the UK.  177 
 178 
The median time from first TED symptoms to review in a specialist eye clinic 179 
was 7 (range 0-600) months (Figure 1), this comparing well with a European 180 
multi-centre study that reported a median of 9 months in 2012 from first TED 181 
symptoms to diagnosis, and then a further median of 6 months from diagnosis 182 
to first specialist clinic appointment.15 Our study took place two years after the 183 
PREGO study15 and our shorter timelines may be attributed to a general 184 
improvement in TED awareness and access to specialist treatment; 185 
alternatively, our results might suggest that the UK National Health Service 186 
(NHS) is performing better than European Healthcare systems in this regard.  187 
 188 
Patients with uncontrolled thyroid function are more likely to develop TED and 189 
have more severe disease20,21 and 54% of our patients did not know their 190 
current thyroid status: over half (54%) of patients were unsure of how long it 191 
took for their thyroid levels to become normal after diagnosis of thyroid eye 192 
disease, 18% were unaware of any relapses of hyperthyroidism, and 14% 193 
patients did not know if they had become hypothyroid in past 2 years.  As 194 
current guidance recommends prompt achievement and maintenance of a 195 
euthyroid state in patients with newly diagnosed TED,4,12 patients should be 196 
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encouraged to monitor their thyroid status and be informed of the association 197 
between uncontrolled thyroid levels and likelihood of more severe disease. 198 
This is in keeping with UK Government policy in which the NHS Outcomes 199 
Framework 2015/6 pledges improved support for people in managing their 200 
chronic disease.22 Emphasis should be placed on achieving and maintaining 201 
normal thyroid levels, and such knowledge might promote improved 202 
compliance with medications and management of thyroid dysfunction. All 203 
doctors (General practitioners, Endocrinologists and Ophthalmologists) 204 
involved in care of patients with TED should keep them informed of their 205 
thyroid status and improved access of patients to their health records and test 206 
results may facilitate this; NHS England has declared that, by April 2016, 207 
online patient records should include test results accessible to the patient.23  208 
 209 
RADIOIODINE AND STEROID PROPHYLAXIS 210 
All patients in our study who received radioiodine for active TED were given 211 
prophylactic steroids,10 but 7/12 (58%) patients having radioiodine developed 212 
TED only after the treatment.  In line with earlier studies,24 5 of these 7 (71%) 213 
were smokers with poor thyroid control – that is, 4/7 had relapse of 214 
hyperthyroidism, and 4/7 had been hypothyroid in the preceding 2 years). 215 
These findings confirm the deleterious association of both smoking and 216 
thyroid dysfunction with TED: two key factors that have been consistently 217 
associated with worse outcomes.24-28 218 
 219 
SMOKING AND PATIENT AWARENESS OF ITS IMPACT ON AUTOIMMUNE 220 
THYROTOXICOSIS AND TED 221 
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It is repeatedly reported that the proportion of smokers in cohorts with TED is 222 
higher than the general population,15 and in our study, this was 30% current 223 
smokers, compared to 19% of the UK population.29 The numbers were even 224 
higher in Europe with 40% current smokers reported by Perros et al15 in their 225 
European-based prospective observational study of 269 new referrals with 226 
Graves’ orbitopathy compared to 28% of the overall adult population. Europe 227 
has the highest prevalence of tobacco smoking in the world (28% vs. 21% 228 
world adult population).30  229 
 230 
The association between smoking and TED is well-established: smoking has 231 
a dose-dependent association with severity of TED,26 is associated with 232 
exacerbation of TED after radio-iodine therapy, and is an independent risk 233 
factor for a poor response to immunosuppression.28  The exact mechanisms 234 
underlying this relationship are not yet clearly defined, although oxidants and 235 
free radicals contained in tobacco smoke are thought to increase oxidative 236 
stress.31  Hyaluronic acid production and adipogenesis are stimulated by 237 
cigarette smoke in a dose-dependent manner.32  238 
 239 
Our study suggests that not enough patients are being provided with advice 240 
about smoking cessation, or information about the impact of smoking on TED 241 
and control of thyroid function. Most patients were unaware that smoking 242 
increases the risk of worse TED, reduces the effectiveness of treatments for 243 
TED, and reduces the chance of being cured of hyperthyroidism. (Table 2).  244 
More than one-third (37%) of our current smokers had not been offered 245 
smoking cessation advice, and yet a quarter of patients who had been 246 
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smokers at the time of first thyroid diagnosis subsequently stopped; this latter 247 
figure is a higher than expected, as a meta-analysis of smoking cessation 248 
rates reporting only a 7% rate after intervention with nurse-led patient 249 
education.33 This might suggest that educating patients about the impact of 250 
smoking on their disease can be effective in TED.34  251 
 252 
Since smoking is such an important modifiable risk factor, it is imperative that 253 
all current smokers with thyroid gland disease are provided with smoking 254 
cessation support.4,10 The 5-year target is: all patients seen in the specialist 255 
eye clinic should be provided with verbal information on the impact of smoking 256 
on TED and all current smokers should receive written information on 257 
smoking cessation. Patient-led organisations such as the British Thyroid 258 
Foundation35 and the Thyroid Eye Disease Charitable Trust36 play a major role 259 
in supporting patients with their disease and are an important source of 260 
disease-specific information. In accordance with NICE guidance, all current 261 
smokers in the UK should be offered a range of cessation strategies – for 262 
example, smoking cessation medications, cognitive behaviour therapy, 263 
acupuncture - by their General Practitioner as part of NHS Stop Smoking 264 
Services.37  265 
 266 
TED CLASSIFICATION 267 
At first ophthalmic assessment, our patients had more active and more severe 268 
disease than that reported by Perros et al in 2012 (active disease 65% vs. 269 
36.8%; mild disease 43% vs. 60.5% respectively)15 (Figure 3). This may be 270 
attributed to earlier diagnosis of TED in our study (median 2 vs. 9 months) 271 
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and this difference may be independent of smoking habits since more severe 272 
disease might be expected in Europe, where more patients smoke.15,30 273 
 274 
LIMITATIONS AND FINDINGS OF THE STUDY  275 
The study is limited by a lack of independent validation of patient responses to 276 
the questionnaire. Information about management of thyroid dysfunction was 277 
collected solely from the patient’s testimony. The questionnaire did not include 278 
questions on past medical history including diabetic status, or current 279 
medication including anti-thyroid medication and selenium supplementation. 280 
As such, the history of thyroid status, treatment and current thyroid status 281 
were unverified from medical records. This limits conclusions that can be 282 
drawn about thyroid status at the time of specialist ophthalmic assessment 283 
and the incidence of relapse of thyrotoxicosis. Furthermore, since 284 
monotherapy with anti-thyroid drugs such as thiamazol may lead to poorly 285 
controlled thyroid levels, and given that the dose-response relationship of 286 
selenium levels may be non-linear in diabetics38, in addition to concerns that 287 
high selenium levels may increase the risk of high grade prostate cancer39, 288 
future studies in this area may benefit from collecting data on the type of 289 
thyroid medication used, selenium supplementation and diabetic status. 290 
 291 
The study did not include the paediatric population and therefore cannot draw 292 
any conclusions as to the current level of care for children with thyroid eye 293 
disease in the United Kingdom.  The authors would welcome future research 294 
in this patient demographic. 295 
 296 
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As a result of this study, we have gained a new insight into the current level of 297 
care of patients with TED in the United Kingdom, and this data provides a 298 
baseline against which the Amsterdam Declaration targets can be assessed 299 
in the future.  The study has generally shown a consistent pattern of patient 300 
profiles, knowledge and management across the different recruiting centres, 301 
but patients would appear to be still waiting a long time not only from first 302 
symptoms to diagnosis, but also from diagnosis to ophthalmic assessment. 303 
The findings of this study support changes to practice particularly with respect 304 
to patient education and awareness of disease and the factors which 305 
influence its progression and prognosis, namely thyroid dysfunction and 306 
smoking. This is in line with the Amsterdam Declaration recommendation of 307 
vigorous anti-smoking measures.  308 
 309 
In this study, we found complete adherence to the Amsterdam Declaration 310 
recommendation that all patients with thyroid eye disease undergoing 311 
radioiodine therapy should have prophylactic steroids to prevent worsening of 312 
their disease. The study has enabled greater definition of national 5-year 313 
targets based on the goals of the Amsterdam Declaration and this will 314 
facilitate planned future re-audit. 315 
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Table 1. To show the baseline characteristics and the distribution of the 444 
patients across the different specialist eye centres involved in the study. 445 
Key: MEH = Moorfields Eye Hospital, London; Notts = Nottingham University 446 
Hospitals NHS Trust; QVH = Queen Victoria Hospital, East Grinstead; Other = 447 
questionnaires of indeterminate origin (that is, returned without sufficient 448 
information to determine which tertiary centre they were from). 449 
 450 
Figure 1. To show the median time (months) from first symptoms of thyroid 451 
eye disease to specialist eye clinic appointment. Key: MEH = Moorfields Eye 452 
Hospital, London; Notts = Nottingham University Hospitals NHS Trust; QVH = 453 
Queen Victoria Hospital, East Grinstead; Other = questionnaires of 454 
indeterminate origin (that is, returned without sufficient information to 455 
determine which tertiary centre they were from). 456 
Figure 2. To show the frequency and range of smoking cessation support 457 
offered to patients. Key: CBT = Cognitive behavioural therapy; Written info = 458 
written information. 459 
Figure 3. To show the distribution of TED disease activity and severity. Key 460 
CAS = Clinical activity score. 461 
 462 
Table 2. To show the variation of patient awareness of the impact of smoking 463 
on thyroid eye disease, the efficacy of treatment of thyroid eye disease and 464 
Graves’ disease across the different specialist eye clinics. Key: MEH = 465 
Moorfields Eye Hospital, London; Notts = Nottingham University Hospitals 466 
NHS Trust; QVH = Queen Victoria Hospital, East Grinstead; Other = 467 
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questionnaires of indeterminate origin (that is, returned without sufficient 468 
information to determine which tertiary centre they were from). 469 
 470 
Appendix 1 471 
Questionnaire: data collection proforma. 472 
 473 
Appendix 2  474 
Signatories of the Amsterdam Declaration 475 
International Professional Organisations 476 
Academia Ophthalmologica Europea 477 
Academia Ophthalmologica Internationalis 478 
American Thyroid Association 479 
Asia-Oceania Thyroid Association 480 
Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgery 481 
Endocrine Society 482 
European Association for Vision and Eye Research (EVER) 483 
European Group on Graves’ Orbitopathy 484 
European Society of Endocrinology 485 
European Society of Orbital Plastic Reconstructive Surgery 486 
European Thyroid Association 487 
Iberico-American Society of Ophthalmic Plastic and Orbital Surgery 488 
International Thyroid Eye Disease Study Group 489 
Latin-American Thyroid Society 490 
World Society of Pediatric Ophthalmology and Strabismus (WSPOS) 491 
 International thyroid patient association 492 
 21 
Thyroid Federation International 493 
 National professional organisations 494 
All India Ophthalmological Society 495 
American Association of Clinical Endocrinologists 496 
Argentina Council of Ophthalmology (Consejo Argentino de Oftalmologia) 497 
Argentina Society of Ophthalmology (SAO) 498 
Belgian Endocrine Society 499 
Belgian Thyroid Club 500 
Bielschowsky-Gesellschaft fur Schielforschung und Neuroophthalmologie 501 
British Oculoplastic Surgery Society 502 
British Thyroid Association 503 
Chinese Society of Ophthalmology 504 
Cyprus Endocrine Society 505 
Danish Thyroid Association 506 
Dutch Endocrine Society 507 
Finnish Endocrine Society 508 
French Endocrine Society 509 
French Society of Ophthalmic Plastic Reconstructive and Aesthetic Surgery 510 
German Endocrine Society 511 
The Amsterdam Declaration on Graves’ Orbitopathy 269 512 
German Thyroid Board 513 
German Society of Ophthalmology (Deutsche Ophthalmologische 514 
Gesellschaft) 515 
Hellenic Endocrine Society 516 
Hellenic Society of Ophthalmic Plastic and Reconstructive Surgery 517 
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Irish Endocrine Society 518 
Italian Association of Medical Endocrinologists (Associazione Medici 519 
Endocrinologi) 520 
Italian Society of Endocrinology 521 
Italian Society of Ophthalmic Plastic Surgery (Società Italiana di Chirurgia 522 
Oftalmoplastica, SICOP) 523 
Italian Thyroid Association 524 
Japan Thyroid Association 525 
Japanese Society of Ophthalmology 526 
Macedonian Endocrine Association 527 
Oculoplastic Association of India 528 
Ophthalmological Society of Portorico (Sociedad Puertorriqueña de 529 
Oftalmología) 530 
Philippine Society of Ophthalmic Plastic and Reconstructive Surgery 531 
(PSOPRS) 532 
Philippine Academy of Ophthalmology (PAO) 533 
Polish Thyroid Society 534 
Romanian Society for Endocrinology 535 
Royal College of Ophthalmologists (UK) 536 
Serbian Endocrine Society 537 
Slovak Endocrine Society 538 
Società Oftalmologica Italiana 539 
Society for Endocrinology (UK) 540 
South African Society of Oculoplastic Surgeons 541 
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Spanish Society of Ophthalmic Plastic and Orbital Surgery (Sociedad 542 
Espanola de 543 
Cirurgia Plastica Ocular y Orbitaria, SECPOO) 544 
Swiss Endocrine and Diabetes Society (SGED/SSED) 545 
Turkish Society for Endocrinology and Metabolism 546 
 National thyroid patient organisations 547 
Association “Vivre sans Thyroïde” 548 
British Thyroid Foundation 549 
Finnish Thyroid Foundation 550 
Georgian Union of Diabetes and Endocrine Associations (GUDEAS) 551 
Italian Thyroid Patient Association 552 
La Asociación Mexicana de Tiroides 553 
Nederlandse Vereniging van Graves’ patienten 554 
Norsk Thyreoideaforbund 555 
Ohne Schilddruse leben e.V. 556 
Schilddrusen-Liga Deutschland e.V. 557 
Schildklierstichting Nederland (Thyroid Patients Organization of the 558 
Netherlands) 559 
Svenska Sköldkörtel Föreningen. 560 
The Australian Thyroid Foundation Ltd. 561 
Thyroid Australia 562 
Thyroid Eye Disease charitable trust (UK) 563 
Thyreoidea Landsforeningen 564 
Instituto da Tiroide 565 
Japan Thyroid Foundation 566 
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Thyroid Foundation of Canada / La Fondation canadienne de la Thyroïde 567 
Thyroid Foundation of St. Petersburg 568 
United States of America Graves’ Disease Foundation 569 
Verein Schilddru sengruppe Schweiz 570 
